Advantages of Biocytogen's Novel bsADC Platform

• RenLite-derived common light chain antibodies are easy to assemble into BsAb with low mismatch rate and ideal physiochemical properties.
• Combined with target gene knockout strategy, RenLite KO mice can generate antibodies with increased diversity, potentially against novel epitopes and with cross-species reactivity.
• Proprietary linker/payload system BLD1102
• Rapid generation of high-quality BsAbs/BsADCs for high-throughput in vitro and in vivo screening

Discovery of Novel BsADCs:

As part of Biocytogen's Project Integrum, combinations of TAA-targeting antibodies generated from RenLite^® mice are subsequently assembled and evaluated in vivo for pharmacologic efficacy, and subjected to in vitro analyses. The company's large animal translational platform will further screen out products with better translational properties:

Off-the-shelf TAA-targeting Antibodies Available for Flexible Plug & Play